<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="127830">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02010775</url>
  </required_header>
  <id_info>
    <org_study_id>191622-130</org_study_id>
    <nct_id>NCT02010775</nct_id>
  </id_info>
  <brief_title>Botulinum Toxin Type A (BOTOX®) Treatment of Masseter Muscle Hypertrophy</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <authority>Canada: Health Canada</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and efficacy of a range of doses of botulinum toxin Type
      A (BOTOX®) for the treatment of patients with bilateral Masseter Muscle Hypertrophy (MMH).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">November 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Lower Facial Volume Calculated by Digital Imaging</measure>
    <time_frame>Day 90</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Investigator's Assessment of Masseter Muscle Hypertrophy (MMH) using a 5-Point Scale</measure>
    <time_frame>Baseline, Day 90</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Masticatory Muscles, Hypertrophy of</condition>
  <arm_group>
    <arm_group_label>BOTOX® 24U</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Botulinum Toxin Type A (BOTOX®) 24U total dose administered intramuscularly to the bilateral masseter muscles on Day 1 and retreatment at Day 180 if applicable.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BOTOX® 48U</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Botulinum Toxin Type A (BOTOX®) 48U total dose administered intramuscularly to the bilateral masseter muscles on Day 1 and retreatment at Day 180 if applicable.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BOTOX® 72U</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Botulinum Toxin Type A (BOTOX®) 72U total dose administered intramuscularly to the bilateral masseter muscles on Day 1 and retreatment at Day 180 if applicable.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BOTOX® 96U</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Botulinum Toxin Type A (BOTOX®) 96U total dose administered intramuscularly to the bilateral masseter muscles on Day 1 and retreatment at Day 180 if applicable.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (Normal saline) administered intramuscularly to the bilateral masseter muscles on Day 1 and retreatment at Day 180 if applicable.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>botulinum toxin Type A</intervention_name>
    <description>Botulinum toxin Type A (BOTOX®) administered intramuscularly to the bilateral masseter muscles on Day 1 and retreatment at Day 180 if applicable.</description>
    <arm_group_label>BOTOX® 24U</arm_group_label>
    <arm_group_label>BOTOX® 48U</arm_group_label>
    <arm_group_label>BOTOX® 72U</arm_group_label>
    <arm_group_label>BOTOX® 96U</arm_group_label>
    <other_name>BOTOX®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>Normal saline (placebo) administered intramuscularly to the bilateral masseter muscles.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants with Masseter Muscle Hypertrophy Exclusion Criteria:

          -  Diagnosis of Myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral
             sclerosis, or any other condition that might interfere with neuromuscular function

          -  Prior botulinum toxin treatment of any serotype to the masseter muscle or lower face

          -  History of dental or surgical procedure for lower facial shaping or masseter muscle
             reduction

          -  History of or current temporomandibular joint disorder (TMJD) or Class III
             malocclusion.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Allergan Inc.</last_name>
    <email>clinicaltrials@allergan.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.allerganclinicaltrials.com</url>
    <description>More Information</description>
  </link>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 28, 2014</lastchanged_date>
  <firstreceived_date>December 10, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>Botulinum Toxins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
